This legislation proposes to significantly increase the orphan drug tax credit by amending Section 45C(a) of the Internal Revenue Code of 1986. The bill specifically changes the credit amount for qualified clinical testing expenses from 25 percent to 50 percent . The primary purpose of this amendment is to provide a greater incentive for pharmaceutical companies to develop treatments for rare diseases. By restoring the credit to a higher percentage, the bill aims to encourage more research and development in this critical area. These changes will take effect for taxable years beginning after the date of the bill's enactment.